Index RUT
P/E -
EPS (ttm) -5.88
Insider Own 9.03%
Shs Outstand 49.26M
Perf Week 13.91%
Market Cap 705.90M
Forward P/E -
EPS next Y -1.88
Insider Trans -2.47%
Shs Float 44.81M
Perf Month 24.50%
Income -260.15M
PEG -
EPS next Q -1.29
Inst Own 88.63%
Short Float 10.73%
Perf Quarter -10.77%
Sales 86.73M
P/S 8.14
EPS this Y 17.86%
Inst Trans -3.01%
Short Ratio 8.93
Perf Half Y 8.07%
Book/sh 7.97
P/B 1.80
EPS next Y 61.95%
ROA -37.78%
Short Interest 4.81M
Perf Year -21.22%
Cash/sh 6.88
P/C 2.08
EPS next 5Y 13.60%
ROE -60.80%
52W Range 10.49 - 28.80
Perf YTD -20.17%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -50.46%
52W High -50.24%
Beta 1.23
Dividend TTM -
Quick Ratio 3.59
Sales past 5Y 72.63%
Gross Margin 36.92%
52W Low 36.61%
ATR (14) 0.85
Dividend Ex-Date -
Current Ratio 3.59
EPS Y/Y TTM 5.90%
Oper. Margin -304.10%
RSI (14) 63.98
Volatility 7.52% 6.59%
Employees 344
Debt/Eq 0.44
Sales Y/Y TTM -20.90%
Profit Margin -299.97%
Recom 1.22
Target Price 39.11
Option/Short Yes / Yes
LT Debt/Eq 0.32
EPS Q/Q 9.76%
Payout -
Rel Volume 0.59
Prev Close 14.39
Sales Surprise -33.59%
EPS Surprise -9.60%
Sales Q/Q -18.37%
Earnings Aug 01 AMC
Avg Volume 538.80K
Price 14.33
SMA20 17.58%
SMA50 7.93%
SMA200 -13.59%
Trades
Volume 318,287
Change -0.42%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-07-24 Initiated
Goldman
Buy
$38
Mar-11-24 Initiated
H.C. Wainwright
Buy
$36
Mar-08-24 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$20 → $35
Mar-06-24 Upgrade
Leerink Partners
Market Perform → Outperform
$37
Feb-21-24 Resumed
Raymond James
Outperform
$45
Nov-01-23 Initiated
Stifel
Buy
$35
Jun-02-23 Initiated
Robert W. Baird
Outperform
$42
Jun-23-22 Initiated
Berenberg
Buy
$61
Dec-15-21 Initiated
Wedbush
Neutral
$29
Oct-19-21 Resumed
Morgan Stanley
Overweight
$62 → $50
Jan-06-21 Upgrade
Raymond James
Outperform → Strong Buy
$60
Dec-16-20 Initiated
UBS
Buy
$57
Jun-25-20 Resumed
BofA/Merrill
Buy
$9
Jun-25-20 Resumed
BofA/Merrill
Buy
$60
May-13-20 Initiated
RBC Capital Mkts
Sector Perform
$42
Aug-20-19 Upgrade
SVB Leerink
Underperform → Mkt Perform
$38 → $37
Jun-18-19 Reiterated
Chardan Capital Markets
Buy
$145 → $150
Jun-14-19 Resumed
Raymond James
Outperform
Jun-05-19 Reiterated
Chardan Capital Markets
Buy
$127.50 → $145
Feb-25-19 Upgrade
Evercore ISI
In-line → Outperform
Show Previous Ratings
Jul-25-24 07:05AM
Jul-12-24 09:59AM
Jun-27-24 10:05AM
Jun-26-24 04:36PM
Jun-25-24 04:32AM
12:56PM
Loading…
Jun-24-24 12:56PM
07:05AM
Jun-21-24 04:28PM
(Investor's Business Daily)
06:40AM
(Investor's Business Daily)
Jun-18-24 07:05AM
07:02AM
Jun-12-24 08:00AM
07:05AM
Jun-05-24 07:05AM
May-15-24 11:38AM
02:30PM
Loading…
May-10-24 02:30PM
07:05AM
May-09-24 03:53PM
11:11AM
07:11AM
(Thomson Reuters StreetEvents)
03:46AM
May-08-24 09:56PM
05:40PM
04:44PM
(Associated Press Finance)
04:05PM
May-01-24 07:05AM
Apr-24-24 07:05AM
Mar-28-24 01:09PM
07:05AM
Mar-27-24 04:05PM
07:00PM
Loading…
Mar-18-24 07:00PM
Mar-13-24 08:00AM
Mar-11-24 07:05AM
Mar-08-24 01:29AM
Mar-06-24 11:20PM
04:10PM
11:33AM
03:01AM
Mar-05-24 07:05AM
Feb-29-24 04:57PM
(PR Newswire) -12.36%
+21.50%
Feb-28-24 11:05AM
(Thomson Reuters StreetEvents)
09:36AM
Feb-27-24 05:35PM
04:41PM
04:32PM
(Associated Press Finance)
04:05PM
Feb-21-24 07:05AM
Feb-17-24 12:07AM
Feb-08-24 09:36AM
04:50AM
Feb-07-24 11:40AM
07:05AM
Jan-31-24 07:05AM
Jan-18-24 09:01PM
Jan-16-24 02:47PM
Jan-10-24 07:05AM
Jan-09-24 06:20PM
Jan-08-24 07:05AM
Dec-22-23 09:01AM
Nov-29-23 07:05AM
Nov-16-23 09:55AM
Nov-09-23 04:46PM
06:37AM
Nov-08-23 04:42PM
(Associated Press Finance)
04:05PM
Nov-07-23 07:05AM
Nov-03-23 06:53PM
Nov-01-23 07:05AM
Oct-30-23 07:05AM
Oct-05-23 07:05AM
Oct-03-23 04:05PM
Sep-26-23 07:05AM
Sep-05-23 07:05AM
Aug-30-23 07:05AM
Aug-23-23 04:05PM
Aug-02-23 05:55PM
04:41PM
04:05PM
Aug-01-23 04:05PM
Jul-26-23 07:05AM
Jul-24-23 04:05PM
Jul-11-23 07:05AM
Jul-01-23 10:09AM
Jun-27-23 07:05AM
Jun-21-23 08:00PM
Jun-20-23 08:00AM
Jun-04-23 09:15AM
Jun-01-23 07:05AM
May-23-23 07:05AM
May-22-23 07:05AM
May-16-23 05:52PM
May-08-23 07:05AM
06:02AM
May-04-23 06:44AM
(Thomson Reuters StreetEvents)
May-03-23 05:55PM
04:47PM
04:05PM
May-02-23 04:53PM
Apr-26-23 08:00PM
04:05PM
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mills Kenneth T. Director Jul 25 '24 Option Exercise 3.76 15,369 57,787 423,404 Jul 26 05:00 PM Mills Kenneth T. Director Jul 25 '24 Sale 13.96 15,369 214,501 408,035 Jul 26 05:00 PM Mills Kenneth T. Director Jul 24 '24 Option Exercise 3.76 12,221 45,951 420,256 Jul 26 05:00 PM Mills Kenneth T. Director Jul 24 '24 Sale 13.78 12,221 168,433 408,035 Jul 26 05:00 PM Mills Kenneth T. Director Jul 17 '24 Option Exercise 3.76 2,210 8,310 410,245 Jul 18 05:05 PM Mills Kenneth T. Director Jul 17 '24 Sale 13.77 2,210 30,440 408,035 Jul 18 05:05 PM Mills Kenneth T. Director Jul 16 '24 Option Exercise 3.76 200 752 408,235 Jul 18 05:05 PM Mills Kenneth T. Director Jul 16 '24 Sale 13.76 200 2,752 408,035 Jul 18 05:05 PM KARABELAS ARGERIS N Director Jul 01 '24 Option Exercise 3.76 10,000 37,600 21,286 Jul 03 07:55 AM KARABELAS ARGERIS N Director Jul 01 '24 Sale 11.27 10,000 112,691 11,286 Jul 03 07:55 AM Mills Kenneth T. President and CEO May 14 '24 Option Exercise 3.76 15,000 56,400 423,035 May 16 05:06 PM Mills Kenneth T. President and CEO May 14 '24 Sale 15.81 15,000 237,222 408,035 May 16 05:06 PM Mills Kenneth T. President and CEO Apr 15 '24 Option Exercise 3.76 15,000 56,400 423,035 Apr 17 05:05 PM Mills Kenneth T. President and CEO Apr 15 '24 Sale 18.19 15,000 272,871 408,035 Apr 17 05:05 PM Vasista Vittal Chief Financial Officer Mar 19 '24 Option Exercise 3.76 20,041 75,354 246,534 Mar 21 05:20 PM Mills Kenneth T. President and CEO Mar 14 '24 Option Exercise 3.76 15,000 56,400 423,035 Mar 18 05:03 PM Mills Kenneth T. President and CEO Mar 14 '24 Sale 21.86 15,000 327,942 408,035 Mar 18 05:03 PM PAKOLA STEVE Chief Medical Officer Mar 05 '24 Option Exercise 22.25 12,878 286,536 120,070 Mar 07 06:05 PM PAKOLA STEVE Chief Medical Officer Mar 05 '24 Sale 28.36 12,878 365,220 107,192 Mar 07 06:05 PM Mills Kenneth T. President and CEO Feb 14 '24 Option Exercise 3.76 15,000 56,400 423,035 Feb 16 06:28 PM Mills Kenneth T. President and CEO Feb 14 '24 Sale 16.76 15,000 251,349 408,035 Feb 16 06:28 PM Mills Kenneth T. President and CEO Jan 16 '24 Option Exercise 3.76 45,000 169,200 453,035 Jan 18 06:39 PM Mills Kenneth T. President and CEO Jan 16 '24 Sale 15.18 45,000 682,992 408,035 Jan 18 06:39 PM PAKOLA STEVE Chief Medical Officer Jan 03 '24 Sale 17.39 17,237 299,789 107,192 Jan 04 04:23 PM Mills Kenneth T. President and CEO Dec 19 '23 Option Exercise 3.66 45,000 164,835 400,289 Dec 21 01:38 PM Mills Kenneth T. President and CEO Dec 19 '23 Sale 19.68 45,000 885,825 355,289 Dec 21 01:38 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite